TipRanks
After a volatile first quarter, Q2 has kicked off in style, and the major indexes sit at or hover near all-time highs. The government bond market has also been steadying as yields have pulled back after rising higher earlier in the year, soothing investor fears that inflation could get out of hand. Moreover, the economic recovery seems to be gathering steam at a faster pace than anticipated. We had been expecting the data to improve about this time, and early signals are that the recovery is absolutely on track, said Hugh Gimber, J.P. Morgans global market strategist. This is the period where the forecast of a strong recovery in growth is starting to look more like the fact of a strong recovery in growth. Against this backdrop, the analysts at J.P. Morgan have pinpointed 2 names which they believe are set for strong growth in the year ahead; both are expected to handsomely reward investors with at least 80% of gains over the coming months. We ran them through TipRanks database to see what other Wall Street's analysts have to say about them. Tencent Music Entertainment (TME) Well start in China, where Tencent Music Entertainment is the offspring of Chinas giant online venture company, Tencent, and Spotify, the Swedish streaming company that makes music and playlists easy. Tencent Music has seen consistently strong sales and earnings for the past year, with the top line growing year-over-year in each quarter of 2020. The Q4 report showed $1.26 billion in the top line, the highest in the last two years, along with 12 cents per share in earnings, up 33% year-over-year. Strong streaming revenue, which showed 29% growth, helped drive the results. And, Tencent Music, through its variety of apps, is the top music streaming service in the Chinese online market as shown by the 40.4% yoy increase in paid subscribers during Q4. In its quarterly results, the company reported 4.3 million net new users in Q4, to reach 56 million active premium accounts across its apps. That said, the stock has pulled back sharply recently, as like many other high-flying growth names, worries regarding an overheated valuation have come to the fore. But pullbacks often spell opportunity, and covering the stock for JPM, Alex Yao notes the strong subscription growth, as well as the potential in the companys other businesses, online ads and long-form audio, for monetization. We believe TME is entering a healthy development cycle with successive growth engines: 1) music subscription remains the core revenue driver with consistent paying ratio improvement, 2) ads revenue ramps up quickly, and 3) active investments in long-form audio initiative, which could become a new growth driver in 2022 and afterwards," Yao noted. To this end, Yao puts a $36 price target on TME, suggesting a one-year upside of 84%, to back his Overweight (i.e. Buy) rating on the stock. (To watch Yaos track record, click here) Overall, TME has a thumbs up from Wall Street. Of the 11 reviews on record, 7 are to Buy, 3 are to Hold, and 1 says Sell, making the analyst consensus a Moderate Buy. The shares are priced at $19.50, and their $30.19 average price target implies an upside of 55% for the months ahead. (See TME stock analysis on TipRanks) Y-mAbs Therapeutics (YMAB) The next JPM pick were looking at is Y-mAbs, a late-stage clinical biopharma company with a focus on pediatric oncology. The company is working on the development and commercialization of new antibody-based cancer therapeutics. Y-mAbs has one medication Danyelza approved for use to treat neuroblastoma in children age 1 and over, and a broad and advanced pipeline of drug candidates in various stages of the clinical process, as well as five additional products in pre-clinical research stages. Having an approved drug is a holy grail for clinical biopharmaceutical companies, and in 4Q20 Y-mAbs saw considerable income from Danyelza. The company announced at the end of December that it had agreed to sell the Priority Review Voucher for the drug to United Therapeutics for $105 million. Y-mAbs will retain the rights to 60% of the net proceeds from the sale, under an agreement with Memorial Sloan Kettering. Also in December, the company announced a license agreement with SciClone. The partnership gives Y-mAbs and Danyelza an opening for treating pediatric patients in China. The agreement includes Mainland China, Taiwan, Hong Kong, and Macau, and is worth up to $120 million for Y-mAbs. The company has entered other agreements making Danyelza available in Eastern Europe and Russia. Danyelza is Y-mAbs flagship product, but the company also has omburtamab in advanced stages of the pipeline. This drug candidate saw a setback in October last year, when the FDA refused to file the company's Biologics License Application, proposed for the treatment of pediatric patients with CNS/leptomeningeal metastasis. Y-mAbs has been in steady communication with the FDA since then, with a new target date for the BLA at the end of 2Q21 or early in 3Q21. These two drugs one approved and one not yet form the basis of the JPM outlook on this stock. Analyst Tessa Romero writes, Our thesis revolves around the de-risked nature of the pediatric oncology pipeline. Our recent KOL feedback is enthusiastic about use of lead asset Danyelza in patients with high-risk neuroblastoma (NB). For second lead asset omburtamab in NB metastatic to the central nervous system (CNS/LM from NB), while the Refuse to File last year and subsequent regulatory delays were certainly disappointing, we still see a high probability of approval for the product in the 2Q/3Q22 timeframe Looking ahead, Romero sees an upbeat outlook for the company: Coupling our anticipation of a healthy launch for Danyelza, with regulatory/clinical momentum expected in the near- to mid-term, we see shares poised to rebound and see an attractive buying opportunity at current levels. The analyst puts a $52 price target on YMAB shares, implying an upside of 86% for the year ahead, and supporting an Overweight (i.e. Buy) rating. (To watch Romeros track record, click here) Overall, the Wall Street reviews break down 3 to 1 in favor of Buys versus Holds on Y-mAbs, giving the stock a Strong Buy consensus rating. The shares have an average price target of $61.25, suggestive of a 121% upside potential this year. (See YMAB stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
See the rest here:
The National Archives won't be able to host Donald Trump's tweets on Twitter - Yahoo Tech
- 'Donald Trump Did This': How to Beat MAGA on Border Security - The Bulwark - April 29th, 2024 [April 29th, 2024]
- Potential Trump running mate JD Vance and Donald Trump Jr. have become so close that they text or talk on a 'nearly ... - Business Insider - April 29th, 2024 [April 29th, 2024]
- Trump Second Term: How the World and U.S. Allies Can Prepare for the Election - Foreign Policy - April 29th, 2024 [April 29th, 2024]
- Poll: Biden and Trump supporters sharply divided by the media they consume - NBC News - April 29th, 2024 [April 29th, 2024]
- Master Calendar of Trump Court Dates: Criminal and Civil Cases - Just Security - April 29th, 2024 [April 29th, 2024]
- Donald Trump's Sleepy, Sleazy Criminal Trial - The New Yorker - April 29th, 2024 [April 29th, 2024]
- Trump, GOP seize on campus protests to depict chaos under Biden - The Washington Post - April 29th, 2024 [April 29th, 2024]
- UK briefing: How Donald Trump plans to survive hush money trial with his campaign intact newsletter - The Guardian - April 29th, 2024 [April 29th, 2024]
- Opinion | We Are Talking About the Manhattan Case Against Trump All Wrong - The New York Times - April 29th, 2024 [April 29th, 2024]
- Election 2024: Biden jokes, Trump still leads and updates from the Sunday shows. - The New York Times - April 29th, 2024 [April 29th, 2024]
- Donald Trump Pans White House Correspondents' Dinner: 'Colin Jost BOMBED' - The Daily Beast - April 29th, 2024 [April 29th, 2024]
- Trump's Trial Could Bring a Rarity: Consequences for His Words - The New York Times - April 29th, 2024 [April 29th, 2024]
- Donald Trump Bemoans Really Bad WHCD, Biden & Colin Jost After All Mock Much Indicted Ex-POTUS - Deadline - April 29th, 2024 [April 29th, 2024]
- The Supreme Court's epic failure in dealing with Trump's cases - The Hill - April 29th, 2024 [April 29th, 2024]
- Donald Trump: In America's most important swing state, a key Biden group wants to hand the presidency to Trump. - Slate - April 29th, 2024 [April 29th, 2024]
- Donald Trump Is Being Ritually Humiliated in Court - The New Yorker - April 29th, 2024 [April 29th, 2024]
- Joe Biden trails Donald Trump in new national poll on 2024 election - USA TODAY - April 29th, 2024 [April 29th, 2024]
- Amid Cases on Abortion and Trump, Roberts Reflects on Supreme Court's Work - The New York Times - April 29th, 2024 [April 29th, 2024]
- Donald Trump Is Used to the Finer Things in Life. At the Courthouse, 'He's Miserable.' - The Wall Street Journal - April 29th, 2024 [April 29th, 2024]
- How Trumps Rhetoric at Rallies Has Escalated - The New York Times - April 29th, 2024 [April 29th, 2024]
- The Supreme Court Appears Poised to Protect the Presidencyand Donald Trump - The New Yorker - April 29th, 2024 [April 29th, 2024]
- The Supreme Court seems divided over Donald Trump's immunity - The Economist - April 29th, 2024 [April 29th, 2024]
- John Dean Says 1 Thing 'Keeping Me On The Edge Of My Seat' In Trump Trial - Yahoo! Voices - April 29th, 2024 [April 29th, 2024]
- Five Moments That Have Defined Donald Trump's Trial So Far - The New York Times - April 29th, 2024 [April 29th, 2024]
- How Trumps trial is playing, politically - The Washington Post - April 29th, 2024 [April 29th, 2024]
- Opinion | The Ukraine aid vote helps, but U.S. allies complacency would be unwise - The Washington Post - April 29th, 2024 [April 29th, 2024]
- Hey, SCOTUS your hypocrisy is showing - The Hill - April 29th, 2024 [April 29th, 2024]
- Bill Barr Is Happy to Debase Himself for Donald Trump Again Mother Jones - Mother Jones - April 29th, 2024 [April 29th, 2024]
- The Supreme Court is likely to place Donald Trump above the law in its immunity case - Vox.com - April 29th, 2024 [April 29th, 2024]
- RFK is openly gunning for Trump voters now and Republicans are starting to worry - Salon - April 29th, 2024 [April 29th, 2024]
- Trump Pushes Immigration Conspiracy Theories and Mass Deportations - The New York Times - February 5th, 2024 [February 5th, 2024]
- Nikki Haley makes surprise appearance on SNL, mocking Donald Trump and Joe Biden - NPR - February 5th, 2024 [February 5th, 2024]
- Trump feud with UAW reaches fever pitch - The Hill - February 5th, 2024 [February 5th, 2024]
- Donald Trump tightens his grip on GOP, bolsters ties with Mike Johnson - USA TODAY - February 5th, 2024 [February 5th, 2024]
- 1/31/24 - 2024 Matchups: Biden Opens Up Lead Over Trump In Head-To-Head, Quinnipiac University National Poll ... - Quinnipiac University Poll - February 5th, 2024 [February 5th, 2024]
- Here's how 2 sentences in the Constitution rose from obscurity to ensnare Donald Trump - Yahoo News - February 5th, 2024 [February 5th, 2024]
- Donald Trump floats tariff of more than 60% on imports from China and denies it would start a trade war - Fortune - February 5th, 2024 [February 5th, 2024]
- Jeffries on House Republicans: Wholly owned subsidiaries of Donald Trump - The Hill - February 5th, 2024 [February 5th, 2024]
- Ex-DOJ Official Says He's 'Now At The Freakout Stage' Over 1 Donald Trump Case - Yahoo News - February 5th, 2024 [February 5th, 2024]
- Nikki Haley to GOP: Let's wait to see if Donald Trump is convicted - USA TODAY - February 5th, 2024 [February 5th, 2024]
- Why Supreme Court appeal will be no 'open mic night' for Donald Trump - USA TODAY - February 5th, 2024 [February 5th, 2024]
- Nikki Haley hits Donald Trump during 'SNL' sketch ahead of SC primary - USA TODAY - February 5th, 2024 [February 5th, 2024]
- Donald Trump's legal fees are draining his campaign funds - The Economist - February 5th, 2024 [February 5th, 2024]
- Donald Trump Mentions These Names When Asked About Vice Presidential Picks - NDTV - February 5th, 2024 [February 5th, 2024]
- Trump's lead over Biden may be smaller than it looks - The Economist - February 5th, 2024 [February 5th, 2024]
- Tory rising star described Donald Trump as 'refreshing' - The Independent - February 5th, 2024 [February 5th, 2024]
- Joe Biden v Donald Trump - where contest will be won and lost - BBC.com - February 5th, 2024 [February 5th, 2024]
- Donald Trump's fed trial on election interference postponed from March - USA TODAY - February 5th, 2024 [February 5th, 2024]
- Inside Trump's growing influence over congressional Republicans - POLITICO - POLITICO - February 5th, 2024 [February 5th, 2024]
- Federal judge postpones Trump's March 4 election interference trial - NPR - February 5th, 2024 [February 5th, 2024]
- Trump Says He Would Not Reappoint Powell as Fed Chair if Elected - Bloomberg - February 5th, 2024 [February 5th, 2024]
- I Prosecuted Donald Trump and Won. Here's How It's Done. - The Daily Beast - February 5th, 2024 [February 5th, 2024]
- Donald Trump Loses London Case Against Ex-MI6 Spy Over Kremlin Dossier - Bloomberg - February 5th, 2024 [February 5th, 2024]
- After Speedy Start, Appeals Court Slows Down on Trump Immunity Decision - The New York Times - February 5th, 2024 [February 5th, 2024]
- Donald Trump and UAW President Shawn Fain exchange barbs: 'Get rid of this dope' - USA TODAY - February 5th, 2024 [February 5th, 2024]
- Donald Trump dispels rumors that he reached out to RFK Jr for VP: Never happened - Fox News - February 5th, 2024 [February 5th, 2024]
- How Donald Trump Got Disqualified From The Ballot And His Entire Candidacy Wound Up Before The Supreme Court - HuffPost - February 5th, 2024 [February 5th, 2024]
- Trump Says Nikki Haley Is Unlikely to Be His Running Mate - The New York Times - January 20th, 2024 [January 20th, 2024]
- Donald Trump Goes From Calm To Indignant In Newly Released Deposition Video Of Civil Fraud Lawsuit - HuffPost - January 20th, 2024 [January 20th, 2024]
- Trump: Haley 'probably ... is not going to be chosen as the vice president' - POLITICO - January 20th, 2024 [January 20th, 2024]
- Trump returns to New Hampshire as primary nears - The Washington Post - January 20th, 2024 [January 20th, 2024]
- Boris Johnson: Trump's return could be 'big win for the world' - POLITICO Europe - January 20th, 2024 [January 20th, 2024]
- Zelenskyy invites Trump to Kyiv POLITICO - POLITICO Europe - January 20th, 2024 [January 20th, 2024]
- 'New Hampshire Is Close to a Make-or-Break for Keeping the Nomination Out of Donald Trump's Hands.' - POLITICO - January 20th, 2024 [January 20th, 2024]
- Trump's pitch in New Hampshire is more about Nikki Haley as he hopes for big win - NPR - January 20th, 2024 [January 20th, 2024]
- Donald Trump's tax cuts would add to American growthand debt - The Economist - January 20th, 2024 [January 20th, 2024]
- Donald Trump's populism is turning off corporate donors - The Economist - January 20th, 2024 [January 20th, 2024]
- Why DeSantis Says Trump's Romp in Iowa Is Actually a Sign of His Weakness - The New York Times - January 20th, 2024 [January 20th, 2024]
- The GOP Is Already Clashing Over Trump's VP Pick - POLITICO - January 20th, 2024 [January 20th, 2024]
- There is still a way to stop Donald Trump but time is running out - The Guardian - January 20th, 2024 [January 20th, 2024]
- The Davos Consensus: Donald Trump Will Win Re-Election - The New York Times - January 20th, 2024 [January 20th, 2024]
- Maine Secretary of State to Appeal Ruling on Her Decision to Exclude Trump From Ballot - The New York Times - January 20th, 2024 [January 20th, 2024]
- Vice President Harris says she's 'scared as heck' that Donald Trump could win - The Associated Press - January 20th, 2024 [January 20th, 2024]
- What is the point of coming second to Donald Trump? - The Economist - January 20th, 2024 [January 20th, 2024]
- Thousands Sign Christian Petition Urging Bishops Not to Back Donald Trump - Newsweek - January 20th, 2024 [January 20th, 2024]
- Why Donald Trump Is Facing E. Jean Carroll in Court a Second Time - The New York Times - January 20th, 2024 [January 20th, 2024]
- Donald Trump Claims He Will Never Allow Creation of CBDC in the US if Reelected - Yahoo Finance - January 20th, 2024 [January 20th, 2024]
- Keller @ Large: What Donald Trump's win in Iowa means for the presidential race - CBS Boston - January 20th, 2024 [January 20th, 2024]
- Donald Trump tries to twist felony charges, lawsuits after Iowa win - USA TODAY - January 20th, 2024 [January 20th, 2024]
- Donald Trump Just Incriminated Himself on Truth Social: Legal Analyst - Newsweek - January 20th, 2024 [January 20th, 2024]